Search results for: Pricing and Reimbursement
Filter search results
Exploring Local NHS Decisions about Investment
4 February 2011
…Health Economics at the University of York. For the coming few months, he will be based at OHE working with Professors Nancy Devlin (OHE’s Director of Research) and with David…
Two Economists Join OHE
10 March 2011
…of competition and regulation, and UK and EU competition law. Prior to the OHE, Arik was with the UK Competition Commission, where he was involved in a wide range of cases…
New: 50 Years of OHE Publications Are Available Online
2 April 2012
…Since the early days of the OHE, another key issue has been how best to define, encourage and evaluate innovation in medicine and medicines. Although perspectives and approaches have evolved,…
New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?
14 June 2012
…higher risk, and public incentives, e.g. allowing only “breakthrough” drugs to be eligible for higher pricing. In comparing R&D performance of companies based in the US and Europe, Prof Riccaboni…
Register Now for the OHE Conference on Drug Development in 2022
2 July 2012
…will affect productivity; how collaboration and competition stimulate learning and commercialisation; and the changing roles of large and small biopharmaceutical companies, academia, governments, and payers. The conference will consider specific…
Spotlight on OHE: Development and Use of Measures of Health Worldwide
16 July 2012
…Netherlands, and the United States – and plans for EQ-5D-5L Value Sets studies in 2012 and beyond. At ISPOR, Nancy also presented two poster sessions that examined the EQ-5D’s use…
OHE Conference on Drug Development in 2022: Update
18 July 2012
…conference, which celebrates OHE’s 50th anniversary, will explore current and emerging critical changes in the science, organisation and economics of drug discovery and development. OHE has added important panelists and…
Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
23 April 2013
…using diagnostic and therapeutic tests in tandem with treatment—“co-dependent technologies”—potentially can maximise both treatment effectiveness and economic efficiency. Advances in science and technology are producing more and better means for…
OHE’s Towse on Challenges in Valuing Genomic Medicines
23 May 2013
…Adrian Towse from Office of Health Economics Related OHE publications and materials include the following. Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2013) Can and should…